Albireo Pharma, Inc. / Fundamentals
Income statement
- Net revenue
€49.24M - Cost of goods sold
€2.19M - Gross profit
€47.06M - SG&A expenses
€67.58M - R&D expenses
€76.11M - EBITDA
-€88.19M - D&A
€368.08K - EBIT
-€105.46M - Interest expenses
€9.79M - EBT
-€115.77M - Tax expenses
€2.10M - Net income
-€117.87M
Cash flow statement
- Net deferred tax
€2.27M - Non-cash items
€16.84M - Changes in working capital
-€17.34M - Operating cash flow
-€98.95M - Capex
€1.06M - Other investing cash flow
€0.00 - Net investing cash flow
-€1.06M - Total cash dividends paid
€0.00 - Issuance of common stock
€17.70M - Debt repayment
€0.00 - Other financing cash flow
€109.85M - Net financing cash flow
€109.85M - Foreign exchange effects
-€1.62M - Net change in cash
€8.46M - Cash at end of period
€233.78M - Free cash flow
-€97.88M
Balance sheet
- Cash and cash equivalents
€190.88M - Cash and short-term investments
€190.88M - Total receivables
€1.74M - Inventory
€2.70M - Other current assets
€9.59M - Total current assets
€204.92M - Property, plant & equipment
€1.12M - Goodwill
€14.81M - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€54.76M - Total non-current assets
€70.69M - Total assets
€275.61M - Accounts payable
€5.96M - Short-term debt
€0.00 - Other current liabilities
€26.49M - Total current liabilities
€32.45M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€157.30M - Total non-current liabilities
€157.30M - Total liabilities
€189.75M - Common stock
€177.61K - Retained earnings
-€361.25M - Other equity
€7.05M - Total equity
€85.86M - Total liabilities and shareholders' equity
€275.61M
Company information
- Market capitalization
€781.21M - Employees
130 - Enterprise Value
€677.78M
Company ratios
- Gross margin
-
95.6% Much better than peer group: -80,784.7% - EBITDA margin
-
-179.1% Much better than peer group: -83,609.4% - EBIT margin
-
-214.2% Much better than peer group: -84,622.3% - EBT margin
-
-235.1% Much better than peer group: -83,984.0% - Net margin
-
-239.4% Much better than peer group: -84,631.4% - ROE
-
-137.3% Much better than peer group: -1,782.3% - ROA
-
-42.8% Much better than peer group: -1,216.7% - Asset turnover
-
17.9% Much worse than peer group: 39.8% - FCF margin
-
-203.1% Much better than peer group: -40,073.0% - FCF yield
-12.8% - Efficiency ratio
279.1% - Net sales per employee
-
€378.78K - Net income per employee
-
-€906.71K